6-KThe Wire
GSK plc files 6-K
Filed Apr 13, 2026 · 2mo ago · Accession 0001654954-26-003422
Plain English
GSK plc announced positive data from its BEHOLD-1 clinical trial for mocertatug rezetecan (Mo-Rez), an antibody-drug conjugate targeting B7-H4. The drug showed objective response rates of 62% in platinum-resistant ovarian cancer and 67% in endometrial cancer, supporting the initiation of five pivotal phase III trials in 2026.
Filing details
- Company
- GSK plc
- Ticker
- GSK
- CIK
- 1131399
- Form type
- 6-K
- Filing date
- Apr 13, 2026
- Report date
- Apr 13, 2026
- Document
- a0706a.htm
- Size
- 50 KB